Hwang_2025_Org.Process.Res.Dev_29_1523

Inhibitors of soluble epoxide hydrolase (sEHIs) have been of interest for treating various diseases in humans and animals. Therefore, various sEHIs have been investigated in several clinical trials. Here, we report the development of a co-amorphous solid dispersion of an sEHI t-TUCB with the amino acid L-arginine. t-TUCB has a very low aqueous equilibrium solubility (0.031 +/- 0.013 microg/mL in pH 6.6 DI water) but possesses a free carboxylic acid. Thus, converting t-TUCB into the corresponding sodium salt improved the water solubility (1.2 mg/mL). However, the sodium salt tended to form insoluble t-TUCB sodium salt aggregates, which is problematic for scale-up of the sodium salt. However, adding L-arginine can de-aggregate t-TUCB sodium salt aggregates. Moreover, the basicity of L-arginine allows us to prepare solid dispersion of t-TUCB directly, which forms a co-amorphous system. The co-amorphous solid dispersion of t-TUCB with L-arginine at a ratio of 1:3 (t-TUCB/Arg (1:3) solid dispersion) not only improved the water solubility (2.2 mg/mL) and dissolution profile (>80% in 10 minutes) of t-TUCB, but also solved the problem of forming insoluble heavy aggregates associated with the sodium salt of t-TUCB. Therefore, the t-TUCB/Arg (1:3) solid dispersion obtained showed 87.1% bioavailability and alleviated LPS-induced pain in rats when orally administered.